CALLA
CALLA tested adding the PD-L1 antibody durvalumab to chemoradiotherapy for locally advanced cervical cancer and found no significant benefit, in contrast to the later positive KEYNOTE-A18 trial of pembrolizumab in a higher-risk population.
Overview
CALLA randomised 770 women with locally advanced cervical cancer (FIGO 2009 stage IB2 to IIB node-positive, or III to IVA) to durvalumab or placebo given with cisplatin-based external beam radiotherapy and brachytherapy and continued for up to 24 cycles. The primary endpoint was progression-free survival.
Durvalumab did not significantly improve progression-free survival, though exploratory analyses suggested benefit in tumours with high PD-L1 expression. KEYNOTE-A18, which enrolled a higher-risk population and used pembrolizumab, reported a positive result the following year, and the reasons for the difference (population, agent, radiotherapy quality) are debated.
Similar pages
not linked directly; found by shared links- TrialPACIFIC-2
Shares Durvalumab, Cisplatin, AstraZeneca and the tag subtype-trials.
- TrialStudy of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
Shares Locally advanced cervical cancer, AstraZeneca, Cervical cancer.
- TrialA Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA)
Shares Locally advanced cervical cancer, AstraZeneca, Cervical cancer.
- TrialORATOR
Shares Cisplatin and the tag subtype-trials.
- TrialKEYNOTE-412
Shares Cisplatin and the tag subtype-trials.
- TrialSHAPE (CCTG CX.5)
Shares Cervical cancer and the tag subtype-trials.
- TrialDESTINY-Gastric02
Shares AstraZeneca and the tag subtype-trials.
- TrialCheckMate 358
Shares Cervical cancer and the tag subtype-trials.